9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 801–900 of 958
Alatawi, A. M. (2023) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.1.6982 · Cited by 1
Dorcélus, L., Alexandre, E. R., Villemenay, C. M., Benjaminel, S. U., & Charles, E. (2024) · Journal of Global Health Reports · doi:10.29392/001c.91452 · Cited by 1
Xu, L., Chen, B., Zhang, H., & Zhu, D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1326611 · Cited by 1
“As diabetes is closely related to CVD and the above two drugs are increasingly used in clinical practice, the proportion of patients taking them in combination is gradually increasing.”
BackgroundInfluentialDiabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Choi, C. H., Singh, S., Cheung, A. T., Vanneman, M. W., & Madhok, J. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.03.007 · Cited by 2
Rojbi, I., Kalthoum, M., Mekni, S., Bouzid, K., Khiari, K., & Nacef, I. B. (2023) · PubMed Central · Cited by 6
Ounaissa, K., Madhbouh, M., Mahjoub, F., Amor, N. B., Abdesselem, H., Lahmar, I., Gammoudi, A., Amrouche, C., & Kamoun, H. J. (2024) · La Tunisie Médicale · doi:10.62438/tunismed.v102i4.4629 · Cited by 1
Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide
Kahol, R., Jain, A., Sharma, N., & Mishra, S. K. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun1950 · Cited by 1
Alharbi, M. F. E., Alabbasi, S. M. S., Alshaikh, J. Z., Alqarni, A. M. A., Alshamrani, S. A. M., Samargandi, O. A., Almutairi, R. M., Alamri, S. O. R., Alshehri, I., Almutairi, A. N., et al. (2024) · Evolutionary Studies in Imaginative Culture · doi:10.70082/esiculture.vi.2242 · Cited by 2
O Uso da Semaglutida no Tratamento em Pacientes com Obesidade
da Silva, M. L., & da Silva, P. R. (2024) · Brazilian Journal of Biological Sciences · doi:10.21472/bjbs.v11n25-018 · Cited by 1
Dongre, S. A., Kulkarni, G. A., Thapa, D., Ghade, N. S., Lona, J., Prajapati, H. K., Mehta, H., Guttikar, S., Krishnan, A. R., & Sonar, S. M. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1510 · Cited by 1
Dinčić, M., Čolović, M. B., Todorović, J., Milinković, N., Radosavljević, B., Mougharbel, A. S., Kortz, U., & Krstic, D. Z. (2025) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-025-02098-w · Cited by 1
“The therapeutic algorithm is mainly based on the timely achievement of an individual’s glycated haemoglobin A 1c (HbA 1c ) level, reducing the risk or slowing the progression of acute and chronic complications (macro-and microvascular) and ensuring normal physical activity and lifestyle [2–4].”
Network pharmacology approach for antidiabetic drugs from natural sources
Dagar, N., Kulkarni, Y. A., & Gaikwad, A. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00015-2 · Cited by 1
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
“In its latest recommenda‑ tions for the management of chronic coronary syndrome, the European Society of Cardiology suggested as a class 1, level A recommendation that GLP1RAs can be used to treat T2DM patients with CVD (120).”
InfluentialUhrig, J. L., PAGE, S. O., Mishriky, B. M., Patil, S. P., Powell, J. R., Sewell, K. B., MIAN, M. R., & Cummings, D. M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1599 · Cited by 1
Mannucci, E., Mangia, P. P., & Pradelli, L. (2020) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v21i1s.1490 · Cited by 2
The Rising Cost of Insulin: Practical Tools and Resources
Inteso, C., & Isaacs, D. M. (2021) · ADCES in Practice · doi:10.1177/2633559x20974354 · Cited by 1
To Heart “Fail” or Not? The Expanding Role of SGLT2 Inhibitors
Gordon, M., & Clements, J. N. (2021) · ADCES in Practice · doi:10.1177/2633559x20978321 · Cited by 1
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
Kovalenko, E. V., Витальевна, Л. М., Arabidze, G. G., & Kryakushkin, V. G. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4235 · Cited by 2
Developing an Educational Mobile Game to Provide Diabetes-Awareness Among Children
Selek, M. B., Çiftçiogulları, U. A., Yüce, Y. K., & İşler, Y. (2021) · Journal of Intelligent Systems with Applications · doi:10.64799/joiswa.v4.i1.4 · Cited by 1
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
Cheng, J. W. M., Colucci, V. J., Kalus, J. S., & Spinler, S. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020934001 · Cited by 1
Importance of applying treatment data to ascertain type 1 diabetes cases in health registries
Mosslemi, M., & Wong, N. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002280 · Cited by 1
Ortega-Montiel, J., Montoya, A., Soria-Saucedo, R., Gallegos-Carrillo, K., Ramírez‐Palacios, P., Salmerón, J., & Salazar-Martínez, E. (2022) · Research Square · doi:10.21203/rs.3.rs-1686514/v1 · Cited by 2
Ortega-Montiel, J., Montoya, A., Soria-Saucedo, R., Gallegos-Carrillo, K., Ramírez‐Palacios, P., Salmerón, J., & Salazar-Martínez, E. (2022) · Research Square · doi:10.21203/rs.3.rs-1686514/v2 · Cited by 1
Investigation of the Duodenojejunal Microbiome in Human Obesity
Steinbach, E. (2023) · theses.fr (ABES) · doi:10.70675/b3bdd603z8ac2z40fdza458z28b625e65668 · Cited by 1
Buckley, K. D., & Fairman, K. A. (2020) · Clinical Diabetes · doi:10.2337/cd19-0074
SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
Ersoy, C. (2020) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.674514
Umsetzung leitlinienkonformer antidiabetischer Therapie mangelhaft
Seibold, J. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00626-7
“American Diabetes Association (2020) 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020.”
BackgroundCan exenatide flatten the post-prandial glucose curve in type 1 diabetes?
Boughton, C. K., & Hovorka, R. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3654
Neue Empfehlungen zur Therapie des Typ-2-Diabetes
Müller‐Wieland, D. (2020) · CardioVasc · doi:10.1007/s15027-020-2106-z
Introducing a novel therapy for type 2 diabetes to primary care
Brunton, S. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798686
Importance of modern antidiabetic drugs for the cardiologist and diabetologist
Šmahelová, A. (2020) · Intervenční a akutní kardiologie · doi:10.36290/kar.2020.025
Martínez, L. F. C., de Windt, F., & Ayala-Gutiérrez, M. M. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.015
Safety of Metformin in Hospitalized Patients with COVID-19
Mikhail, N. E., & Wali, S. (2020) · doi:10.36502/2020/droa.6171
Halimi, S. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.10.006
Laugesen, C., Ranjan, A. G., Schmidt, S., Rasmussen, L. N., Nørgaard, O., Christensen, R., & Nørgaard, K. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038970
Komentár k ESC/EASD 2019 Odporúčaniam pre diabetes, prediabetes a kardiovaskulárne ochorenia
Fábryová, Ľ., Martinka, E., & Murín, J. (2020) · Cardiology letters · doi:10.4149/cardiol_2020_4_1
Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes
Hahr, A. J., & Molitch, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_23
Antić, S., & Zdravković, D. (2020) · Acta Medica Medianae · doi:10.5633/amm.2020.0305
Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes
Wong, N. D., & Handelsman, Y. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_12 · Cited by 1
Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus
İmamoğlu, Ş. (2021) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.815794
Watanabe, H., Takahara, M., Katakami, N., & Shimomura, I. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab082
Mason, T. (2020) · TSpace (University of Toronto)
Jang, H. N., & Jung, H. S. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.1.194
Hsueh, L., Hirsh, A. T., Zapolski, T. C. B., de Groot, M., Mather, K. J., & Stewart, J. C. (2021) · Journal of Behavioral Medicine · doi:10.1007/s10865-021-00224-y
Rhee, E. (2021) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2021.3.e4
Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?
Htet, Z. M., & Karim, M. (2021) · Journal of the Royal Society of Medicine · doi:10.1177/01410768211011109
4. Clinical Pharmacology in Heart Failure Patients with Multiple Comorbidities
Shiga, T. (2021) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.52.79
Baviera, M., Genovese, S., Lepore, V. L., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-89359/v1
Ruolo dei farmaci antidiabete nel trattamento della NAFLD
Mantovani, A. (2021) · il Diabete · doi:10.30682/ildia2102b
Kawai, K., Eiki, J., Kanatsuka, A., Motohashi, S., Wakana, A., Hayashi, A., Iglay, K., Yamazaki, K., Tokita, S., & Maegawa, H. (2021) · Diabetology International · doi:10.1007/s13340-021-00514-5
Akut Böbrek Hasarı Olgusunda Metformin İle İlişkili Laktik Asidoz
Balimre, B. Ç., Toksöz, D. Y., Eroğlu, C. E., Şengül, E., & Yılmaz, Z. (2021) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.868292
Zhao, Q. (2021) · Frontiers in Medical Science Research · doi:10.25236/fmsr.2021.030407
Corsino, L., & Mcneill, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-75377-1_17
Standard Pharmacological Treatment of Diabetes Based on the Guidelines
Moon, J. S., & Won, K. C. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_15
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Editorial: Carbohydrate-Restricted Nutrition and Diabetes Mellitus
Westman, E. C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.827990
Pandya, N., & Patel, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-01782-8_38-1
Metabolic and cardiovascular risk factors associated with type 1 Diabetes Mellitus in pediatric age
Araújo, M., & Correia, C. C. (2022) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ar210013
Impact of a Mobile Application Based Intervention on Improving Glycemic ControlPreprint
Rafaqat, W., Belgaumi, S. M., Syed, M. A., & Iqbal, R. (2022) · Research Square · doi:10.21203/rs.3.rs-1251154/v1
Iwamoto, M., Nakanishi, S., Iwamoto, H., Kaneto, H., & Maegawa, H. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0647
Nicolucci, A., & Leonardi, L. (2022) · Medical Devices Evidence and Research · doi:10.2147/mder.s352849
New Kid on the Block: Semaglutide
Siddhanta, S. (2022) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-7079
Guideline‐concordant prescribing or medication adherence: A Medicare Part D predicament
Lussier, M. E., Pradhan, A., & Wright, E. A. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17775
Li, X., Ni, Z., Wang, J., Ye, X., Shen, Y., Liu, R., Pan, W., Cao, H., & Wu, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1647971/v1
Hayek, A. A., Robert, A. A., Saeed, A. H. A., & Dawish, M. A. A. (2022) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514221098415
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23535-1.00008-2
Ulrich, W., Bielohuby, M., Korn, M., Riedel, J., Will, M., & Méndez, M. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14827
Nguyễn, X. T. (2022) · Tập san Khoa học và kỹ thuật trường Đại học Bình Dương · doi:10.56097/binhduonguniversityjournalofscienceandtechnology.v5i2.49
Nanoparticle-assisted oral delivery of small and large peptides
Arora, M., Zou, D., & Kumar, M. N. V. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821061-1.00007-1
Semaglutide: A Strategic Weapon for Primary Care
Jain, A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u3
La patogenesi del diabete mellito: I. Glicogenesi, iperglicemia, glicosuria
Toni, R. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01160-y
Parra-Serrano, G. A., Torres-Langhammer, M. P., Pinto-Arias, A. J., & Gómez, S. E. S. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.4.740
Li, Y., Wu, Y. Y., Shu, Y., Li, S., Pei, J., Chen, H., Liu, S., Xiang, G., Wang, W., Shan, P., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.998210
Adjunctive Therapies for Weight Management in Type 1 Diabetes
Lechner, M. (2022) · ADCES in Practice · doi:10.1177/2633559x221136868
The Heart in Diabetic Hypertensive Patients
Halabi, A., & Marwick, T. H. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_13 · Cited by 1
¬Antidiabetic Activity of Ethanol Extract of Tetracera scandens (L.) Merr. Stems
Fauziah, F., Kardela, W., & Tinsia, D. J. (2022) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v10i5.1176
Sa'idah, R., Christyaningsih, J., Sari, M., & Pavadhgul, P. (2022) · International Journal of Advanced Health Science and Technology · doi:10.35882/ijahst.v2i6.179
Effetto delle nuove e vecchie terapie antidiabetiche su funzione erettile e fertilità maschile
Defeudis, G., Mazzilli, R., Carlomagno, F., Tommaso, A. M. D., Zamponi, V., & Gianfrilli, D. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01240-7
Current Strategies of New Drugs for Diabetes Management
Sarfraz, M., Hafizur, R. M., Ullah, H., Sajid, S., Akhtar, R. W., Noreen, M., Perveen, S., & Khan, M. U. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070005
Ortega-Montiel, J., Montoya, A., Soria-Saucedo, R., Gallegos-Carrillo, K., Ramírez‐Palacios, P., Salmerón, J., & Salazar-Martínez, E. (2023) · Research Square · doi:10.21203/rs.3.rs-1686514/v3
Characteristics of adult-onset auto-immune type 1 diabetes
Kacem, F. H., Jerbi, A., Twaheerah, A. B., abed, W. B., Mnif, M. F., Charfi, N., Elleuch, M., Rekik, N. M., Masmoudi, H., & Abid, M. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.04.009
Vázquez-Agra, N., Fernández-Crespo, S., Marques-Afonso, A.-T., Cruces‐Sande, A., Gouveia, S., Olmos, M. Á. M., & Ameijeiras, Á. H. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.09.026
Dyleva, Y. A., Gruzdeva, O. V., Belik, E. V., Borodkinа, D. A., Sinitskiy, M. Y., Ivanov, S. V., & Барбараш, О. Л. (2023) · Obesity and metabolism · doi:10.14341/omet12743
Traduction et validation en langue française de l’instrument « Diabetes Knowledge Questionnaire »
Helou, N., Rapin, M., Nobre, D., & Zanchi, A. (2023) · Recherche en soins infirmiers · doi:10.3917/rsi.152.0060
Diarrhea and Acute Renal Injury Culminating in Metformin-Induced Lactic Acidosis
El-Reshaid, K., & Al-Bader, A. (2023) · Open Journal of Nephrology · doi:10.4236/ojneph.2023.133018
Ortega-Montiel, J., Montoya, A., Soria-Saucedo, R., Gallegos-Carrillo, K., Ramírez‐Palacios, P., Salmerón, J., & Salazar-Martínez, E. (2023) · Research Square · doi:10.21203/rs.3.rs-1686514/v4
Actualización en Atenciones Médicas Vol. 22
Tenecela, C. E. M., Sanmartín, J. A. S., Guacho, M. J. S., Godoy, Y. M. F., Mora, C. S. C., Andagana, V. V. T., García, K. A. B., Cárdenas, P. J. V., Lara, J. E. R., Pérez, A. S. R., et al. (2023) · Juan Cuevas eBooks · doi:10.56470/978-9942-650-60-3
Keleş, İ., Koyuncu, A., Yava, A., & Olgun, N. (2024) · Bingöl Üniversitesi Sağlık Dergisi · doi:10.58605/bingolsaglik.1419824
Vukov, A., Panić, J. J., Bešter‐Rogač, M., & Vraneš, M. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124353
Uchida, T., Ueno, H., Sekishima, A., Sekishima, H., Konagata, A., Nakamura, T., Kogo, F., Nabekura, H., Tanaka, Y., Shimizu, K., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00710-z
Ming, J., Yu, X., Xu, X., Wang, L. S., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15132754
Ming, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15132742
Ming, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15132763
Ming, J., Yu, X., Xu, X., Wang, L. S., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15132745
A Major Error in Insulin Injection Site
Naina, M. J., Gupta, S., Jothydev, K., Sreelakshmi, R., Ashik, A., Chandran, G. B., Shankar, A., & Kesavadev, J. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_6_24
Péptidos bioactivos derivados de las semillas de frijol (Phaseolus vulgaris L.)
Reyes-Bautista, R., Flores-Sierra, J. D. J., & Xoca-Orozco, L. Á. (2024) · CienciaUAT · doi:10.29059/cienciauat.v19i1.1872
Actualización en Atenciones Médicas Vol. 27
Cajamarca, J. L. L., Espinoza, M. B. V., Gómez, C. P. F., Puchaicela, A. R. E., López, J. F. R., Taipe, P. O. V., Montenegro, G. A. N., Ramos, S. K. B., Albán, A. G. A., Herrera, G. A. M., et al. (2024) · doi:10.56470/978-9942-660-93-0
Rangani, L. A. C., Mendis, B. I. L. M., Rajapakse, I. H., & Dissanayake, A. S. (2024) · Cureus · doi:10.7759/cureus.67509
Steenkamp, D. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch09
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.